Could Assertio Therapeutics Inc (NASDAQ:ASRT) Go Up After Its Newest Short Interest Report?

November 10, 2018 - By Marie Mckinney

The stock of Assertio Therapeutics Inc (NASDAQ:ASRT) registered an increase of 6.03% in short interest. ASRT’s total short interest was 7.88M shares in November as published by FINRA. Its up 6.03% from 7.43M shares, reported previously. With 941,700 shares average volume, it will take short sellers 8 days to cover their ASRT’s short positions. The short interest to Assertio Therapeutics Inc’s float is 14.62%.

The stock increased 7.10% or $0.36 during the last trading session, reaching $5.43. About 1.33M shares traded or 106.33% up from the average. Assertio Therapeutics, Inc. (NASDAQ:ASRT) has declined 9.24% since November 10, 2017 and is downtrending. It has underperformed by 24.86% the S&P500.

Assertio Therapeutics, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. The company has market cap of $347.06 million. It offers Gralise , an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults. It currently has negative earnings. The firm also provides NUCYNTA ER (tapentadol extended release tablet), a product for the management of pain severe enough to long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults; and NUCYNTA IR (tapentadol), a product for the management of moderate to severe acute pain in adults.

More notable recent Assertio Therapeutics, Inc. (NASDAQ:ASRT) news were published by: Seekingalpha.com which released: “Assertio Therapeutics Inc (ASRT) CEO Arthur Higgins on Q3 2018 Results – Earnings Call Transcript” on November 09, 2018, also Benzinga.com with their article: “The Daily Biotech Pulse: Pfizer And Allergan Earnings, CFO Departures At Acadia And Assertio” published on October 30, 2018, Benzinga.com published: “The Daily Biotech Pulse: Nantkwest Reports Positive Cancer Vaccine Trial Results, Sarepta Offering” on November 08, 2018. More interesting news about Assertio Therapeutics, Inc. (NASDAQ:ASRT) were released by: Nasdaq.com and their article: “Assertio Therapeutics Announces the Appointment of Daniel A. Peisert as Senior Vice President and Chief Financial …” published on October 29, 2018 as well as Benzinga.com‘s news article titled: “The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs” with publication date: November 04, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>